Loading clinical trials...
Loading clinical trials...
This study will evaluate the association of non-alcoholic fatty liver disease and coronary artery disease. All patients presenting for coronary angiogram will receive the following examination: * Transient Elastography and Controlled Attenuation Parameter using the FibroScan * blood examination including biochemical markers The results of non-invasive liver steatosis and fibrosis measurement are compared with the results of coronary angiogram concerning the presence or absence of coronary artery disease.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Klinikum der J. W. Goethe-Universität
Frankfurt am Main, Germany
Start Date
June 1, 2012
Primary Completion Date
September 1, 2013
Completion Date
December 1, 2013
Last Updated
July 12, 2012
572
ESTIMATED participants
Transient Elastography (FibroScan), Echosens, Paris, France
DEVICE
Controlled Attenuation Parameter (CAP), Echosens, Paris, France
DEVICE
Lead Sponsor
Johann Wolfgang Goethe University Hospital
NCT06216041
NCT04104321
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02443116